IVIM Health vs Remedy Meds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; IVIM Health shows only a starting-dose or coupon figure (from $192, $117 + $75 program fee), so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; IVIM Health shows only a starting-dose or coupon figure (from $140, $65 + $75 program fee), so no like-for-like comparison is possible.
IVIM Health and Remedy Meds, measure by measure
| Measure | IVIM Health | Remedy Meds |
|---|---|---|
| Tirzepatide, month to month | from $192 (per month, starting-dose price) | $399 (per 28-day cycle) |
| Tirzepatide, lowest printed | $192 ($117 + $75 program fee) | $399 (4-week supply; $279 first month only) |
| Semaglutide, month to month | from $140 (per month, starting-dose price) | $299 (per 28-day cycle) |
| Semaglutide, lowest printed | $140 ($65 + $75 program fee) | $299 (4-week supply; $179 first month only) |
| Dose pricing | priced by dose or not stated | same price at every dose |
| Membership or program fee | about $75 a month | none |
| Computed score | 8 of 40 (position 18 of 27) | 24.3 of 40 (position 7 of 27) |
| FDA warning letters | 721816 (2026-02-20) | 716830 (2025-09-09) |
| November 20 read | first-party read | first-party read |
Strengths and limitations: which fits whom
IVIM Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. Remedy Meds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| IVIM Health | tirzepatide | — | from $192 |
| IVIM Health | semaglutide | — | from $140 |
| Remedy Meds | tirzepatide | — | $399 |
| Remedy Meds | semaglutide | — | $299 |
Regulatory record
FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 716830 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Remedy Meds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, IVIM Health or Remedy Meds?
On compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; IVIM Health shows only a starting-dose or coupon figure (from $192, $117 + $75 program fee), so no like-for-like comparison is possible. On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; IVIM Health shows only a starting-dose or coupon figure (from $140, $65 + $75 program fee), so no like-for-like comparison is possible.
Do IVIM Health and Remedy Meds charge a membership fee?
IVIM Health: about $75 a month on top of medication; Remedy Meds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are IVIM Health and Remedy Meds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- IVIM Health pricing page (read November 20, 2026)
- Remedy Meds pricing page (read November 20, 2026)
- FDA warning letter 721816 to IVIM Health (dated 2026-02-20, posted 2026-03-03)
- FDA warning letter 716830 to Remedy Meds (dated 2025-09-09, posted 2025-09-16)